Phathom Pharmaceuticals, Inc. Non Cash Items (Other)

Non Cash Items (Other) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non Cash Items (Other) growth rates and interactive chart.


Highlights and Quick Summary

  • Non Cash Items (Other) for the quarter ending June 29, 2021 was $4.42 Million (a 5.87% increase compared to previous quarter)
  • Year-over-year quarterly Non Cash Items (Other) increased by 98.38%
  • Annual Non Cash Items (Other) for 2020 was $6.07 Million (a -97.34% decrease from previous year)
  • Annual Non Cash Items (Other) for 2019 was $228 Million (a 455352.0% increase from previous year)
  • Twelve month Non Cash Items (Other) ending June 29, 2021 was $13.4 Million (a 36.75% increase compared to previous quarter)
  • Twelve month trailing Non Cash Items (Other) decreased by -84.86% year-over-year
Trailing Non Cash Items (Other) for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$13.4 Million $9.77 Million $6.07 Million $88.3 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non Cash Items (Other) of Phathom Pharmaceuticals, Inc.

Most recent Non Cash Items (Other)of PHAT including historical data for past 10 years.

Interactive Chart of Non Cash Items (Other) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Non Cash Items (Other) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $4.42 $4.18
2020 $2.54 $2.23 $0.83 $0.47 $6.07
2019 $84.78 $60.3 $82.64 $0.01 $227.73
2018 $0.02 $0.05

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.